{"filings":[{"id":2033401,"accession_number":"0001193125-26-331488","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-08-04T10:50:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q2 2026: Adjusted EPS $0.63, revenue $488M, reaffirms FY EBITDA $280-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $487.8M, up 4.0% YoY; net income $39.8M ($0.49 diluted EPS) vs $39.3M ($0.46) YoY.","Adjusted EPS $0.63 vs $0.53 YoY; Adjusted EBITDA $76.4M vs $73.2M YoY.","Same-unit revenue up 1.9% (reimbursement +4.0%, volume -2.1%); NICU days down 3.2%.","Reaffirmed FY 2026 Adjusted EBITDA guidance of $280M-$300M.","Used $42.7M for share repurchases in Q2; total debt $584M, cash $288.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1858928,"accession_number":"0001193125-26-316225","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-07-24T21:00:13+00:00","items":["5.02","7.01"],"status":"ready","headline":"Pediatrix Medical Group GC Mary Ann Moore to depart Oct 31; David Haddock appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Ann Moore will transition to advisory role until October 31, 2026, then leave the company.","Separation agreement with PMG Services; termination without cause triggers benefits under employment agreement.","David Haddock appointed Executive Vice President, General Counsel and Secretary effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1646317,"accession_number":"0001193125-26-304033","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-07-15T11:00:15+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pediatrix reaffirms FY 2026 Adjusted EBITDA guidance of $280M-$300M; payor mix stable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Payor mix for Q2 2026 remained stable and unchanged relative to recent historical trends and internal expectations.","Company has not experienced unfavorable payor mix shifts reported elsewhere in healthcare sector.","Reaffirms full year 2026 Adjusted EBITDA outlook in range of $280 million to $300 million.","No material changes in other net revenue-related trends compared to recent historical periods.","Earnings conference call scheduled for August 4, 2026 at 9:00 a.m. ET to discuss Q2 results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99527,"accession_number":"0001193125-26-212117","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pediatrix shareholders approve 8M share increase in incentive plan; director Starcher faces 36% withhold vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing authorized shares by 8,000,000.","Director John M. Starcher, Jr. received 46,296,745 votes for (55%) and 25,909,618 against (36% of votes cast excluding broker non-votes).","PricewaterhouseCoopers LLP ratified as auditor for 2026 with 75,519,473 for (97.6% of votes cast).","Advisory vote on named executive officer compensation for 2025 approved with 70,257,832 for (97.3% of votes cast excluding broker non-votes).","All other director nominees received over 98% support from votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99526,"accession_number":"0001193125-26-204982","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q1 GAAP EPS $0.36, Adj. EPS $0.44; revenue $476M, beat expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $476.2M, up 4% YoY from $458.4M; same-unit revenue grew 2.8%.","Adjusted EBITDA $58.2M vs $49.2M YoY; net income $29.6M ($0.36 diluted) vs $20.7M ($0.24).","Same-unit volume down 1.6% (hospital services -1.5%, office -3.3%) but reimbursement up 4.4%.","Reaffirmed FY2026 Adjusted EBITDA guidance range of $280M-$300M.","Used $21.5M for share repurchases and $7.0M for acquisitions in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":476196000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115581,"accession_number":"0001193125-26-058063","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q4 EPS $0.40; Adj. EPS $0.50; guides 2026 EBITDA $280-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $494M, down slightly YoY; same-unit revenue up 4.0%.","Q4 GAAP net income $33.7M ($0.40/share) vs $30.5M ($0.36) prior year; Adjusted EPS $0.50.","Full year 2025 Adjusted EBITDA $275.6M, up from $224M; Adjusted EPS $2.04 vs $1.51.","Preliminary 2026 Adjusted EBITDA guidance $280-300M, above 2025's $275.6M.","Cash from operations $114.6M in Q4; used $64M for share repurchases; total debt $597M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":1913849000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132006,"accession_number":"0001193125-25-261626","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q3 EPS $0.84, revenue $493M; raises FY2025 Adj. EBITDA outlook to $270-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $71.7M ($0.84/share) vs $19.4M ($0.23) year ago; adjusted EPS $0.67 vs $0.44.","Net revenue $492.9M, down 3.6% YoY; same-unit net revenue rose 8.0%.","Adjusted EBITDA $87.3M vs $60.2M; guidance raised to $270-290M from prior range.","Same-unit volume growth of 0.4%; NICU days up 2.2% and reimbursement factors up 7.6%.","Used $20.9M for share repurchases, $19.2M for acquisitions in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":1420078000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148584,"accession_number":"0000950170-25-109777","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pediatrix Medical Group announces $250M share repurchase program with three-year term","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $250M in share repurchases of outstanding common stock over three years.","CEO Mark Ordan cites strong cash flow, current cash balances, and low debt levels as rationale.","Repurchases may be made via open market or privately negotiated transactions, including 10b5-1 plans.","Program may be suspended or discontinued at any time; no obligation to repurchase any specific amount.","Company will weigh repurchases against other strategic uses of cash for long-term shareholder returns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148583,"accession_number":"0000950170-25-102375","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q2 EPS $0.46, Adjusted $0.53; raises FY 2025 EBITDA guidance to $245-255M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $469M; net income $39M vs. loss of $153M a year ago due to non-cash impairment.","Adjusted EBITDA $73M, up from $58M in Q2 2024; raised FY guidance to $245-255M (from $220-240M).","Same-unit revenue +6.4% with neonatology NICU days up 6.0% year-over-year.","Cash from continuing operations $138M; total debt $606M; no revolver borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":927203000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148582,"accession_number":"0000950170-25-092261","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pediatrix appoints Dr. Kurt Newman as independent director effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Newman, former President & CEO of Children's National Hospital for 12 years, appointed to board.","He is a pediatric surgeon and professor emeritus, bringing clinical insight and healthcare leadership.","Receives standard non-employee director compensation; enters indemnification agreement with company.","No arrangements with other persons regarding his appointment; no committee assignments yet determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167434,"accession_number":"0000950170-25-067076","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pediatrix shareholders elect all 8 director nominees, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 management director nominees elected with 70M+ votes each; broker non-votes of ~5.5M.","PricewaterhouseCoopers ratified as auditor for FY2025: 76.5M for, 1.3M against.","Non-binding say-on-pay proposal approved: 67.1M for, 4.95M against, 333K abstain.","Meeting held May 8, 2025; ~77.9M of 85.8M outstanding shares represented (quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167433,"accession_number":"0000950170-25-063946","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q1 adjusted EPS $0.33; raises FY2025 EBITDA guidance to $220-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $458M, down 7% YoY due to dispositions; same-unit revenue grew 6.2% on improved payor mix and volume.","Adjusted EBITDA $49.2M (up 32% YoY); GAAP EPS $0.24 vs $0.05; Adjusted EPS $0.33 vs $0.20.","Raised FY2025 Adjusted EBITDA guidance to $220-240M from $215-235M after strong Q1.","Cash from ops used $116.1M for seasonal incentive comp; total debt $611M, no revolver draw.","Same-unit volume: NICU days +2.0%, hospital-based +1.7%, office-based +2.6% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":458359000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167432,"accession_number":"0000950170-25-055880","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Pediatrix extends Guidehouse services pact to June 30, 2025; adds SOW #2 from July 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PMG Services and Guidehouse amended SOW #1 to extend term from April 19, 2025 through June 30, 2025.","New SOW #2 starts July 1, 2025, with Guidehouse providing services for fixed, variable, and incentive payments.","Incentive payments tied to Guidehouse achieving certain performance metrics under SOW #2.","Agreement originally dated April 19, 2024, between PMG Services (Pediatrix subsidiary) and Guidehouse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184732,"accession_number":"0000950170-25-023723","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q4 net income $30M, Adjusted EPS $0.51, revenue up to $502M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.36 (vs $1.50 loss Q4 2023); Adjusted EPS $0.51 (vs $0.32).","Net revenue $502M, up from $496M; same-unit revenue grew 8.7%.","Adjusted EBITDA $68.7M (vs $50.8M); portfolio restructuring completed by Dec 31, 2024.","Preliminary 2025 Adjusted EBITDA guidance $215M-$235M.","Cash from operations $134.8M; total debt $616M; no revolver borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":2012919000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184731,"accession_number":"0001193125-25-006190","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mark S. Ordan appointed CEO of Pediatrix Medical Group effective Jan 12, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Ordan, 65, appointed CEO; he was CEO from 2020-2022 and most recently Executive Chair, succeeding Dr. Swift.","Employment agreement: $1M base salary, $2M one-time cash retention award, annual bonus target 150% of salary.","Equity transformation award: 640,000 performance share units with stock price hurdles of 125%, 150%, and 175%.","Annual equity grants of at least $5.5M; severance for cause-less termination: 2x base+bonus, 3x under change in control.","Dr. Swift's departure is termination without cause; he will receive severance benefits under prior employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184730,"accession_number":"0001193125-25-004937","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pediatrix appoints Mark Ordan as CEO, expects 2024 adjusted EBITDA to exceed $215M guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark S. Ordan returns as CEO effective immediately, succeeding James D. Swift who will assist transition.","2024 adjusted EBITDA expected at high end of $205M-$215M range or possibly above; results due Feb 20.","Company refocusing on hospital relationships, divesting primary/urgent care clinics, and restructuring leadership.","Ordan led Pediatrix restructuring as CEO from 2020-2022 and has turnaround experience at Sunrise, ManorCare.","Board cites need to accelerate strategy for shareholder value; Ordan served as Executive Chair since Oct 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201311,"accession_number":"0000950170-24-133723","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pediatrix Medical Group announces departure of EVP & Chief Physician Executive Curtis Pickert effective Jan 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Curtis B. Pickert will transition from his roles as EVP, Chief Physician Executive and former COO effective January 31, 2025.","Pickert was notified on November 29, 2024; his departure is a termination without Cause under his employment agreement.","He will receive contractual benefits after executing a general release of claims in favor of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201310,"accession_number":"0000950170-24-119795","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).","GAAP EPS $0.23, down from $0.26 YoY; Adjusted EPS $0.44 vs $0.32; Adjusted EBITDA $60M vs $50.4M.","Exiting almost all office-based practices (except maternal-fetal medicine); expects ~$30M annualized EBITDA benefit by year-end.","Cash from operations $95.7M; total debt $619M, no revolver borrowings; completed hybrid RCM transition.","FY 2024 Adjusted EBITDA guidance $205-215M, implying Q4 roughly $50-60M based on YTD result of $155.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1510555000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217343,"accession_number":"0000950170-24-091185","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pediatrix Medical Group Q2 net loss $153M (-$1.84/share); Adjusted EPS $0.34 vs $0.39; CFO transition planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $153M ($1.84 loss per share) vs net income $28.3M ($0.34 EPS) in Q2 2023, driven by $192.9M impairment.","Adjusted EPS fell to $0.34 from $0.39; Adjusted EBITDA $57.9M vs $59.1M. Revenue $504.3M (+0.7% YoY).","Company exits office-based and primary/urgent care practices; expects ~$30M annualized EBITDA benefit; guidance reaffirmed $200-220M.","CFO transition: Kasandra Rossi appointed to succeed Marc Richards effective ~Oct 1, 2024.","Mary Ann Moore appointed CAO; Dr. Curtis Pickert transitions from COO to Chief Physician Executive (no longer exec officer)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":999397000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237165,"accession_number":"0000950170-24-074283","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pediatrix eliminates EVP role of Lee Wood; departure by July 5, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee A. Wood's role as EVP of National and Market Operations eliminated effective July 5, 2024.","Termination is without cause under second amended employment agreement dated April 2023.","Departure part of company's previously announced continued focus on operating efficiency.","No replacement named; the role is eliminated as part of restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237164,"accession_number":"0000950170-24-066242","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pediatrix Medical Group reiterates 2024 Adj. EBITDA guidance of $200M-$220M, portfolio optimization with $30M impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company exiting office-based practices and primary/urgent care by end of 2024.","Annualized Adj. EBITDA impact of portfolio optimization ~$30M (based on 2023 results).","Reiterates 2024 Adj. EBITDA guidance range of $200M to $220M, including in-year impact.","Focus on operating efficiency and margin stabilization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237163,"accession_number":"0000950170-24-057093","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pediatrix shareholders elect all 9 director nominees, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; votes for ranged from 72.6M to 74.1M, against 0.9M-2.3M.","Ratification of PricewaterhouseCoopers as auditor for 2024: 75.2M for, 2.4M against.","Advisory vote on 2023 executive compensation approved: 71.7M for, 3.3M against, 2.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237162,"accession_number":"0000950170-24-053917","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.","Net income $4M down from $14.2M; GAAP EPS $0.05 vs $0.17.","Adjusted EPS $0.20 vs $0.23; Adjusted EBITDA $37M vs $40.1M.","FY 2024 Adjusted EBITDA guidance reaffirmed $200M-$220M.","Cash used in ops $122.6M; total debt $705M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":495101000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237161,"accession_number":"0000950170-24-048387","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Pediatrix enters 8-year revenue cycle management agreement with Guidehouse","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PMG Services (Pediatrix subsidiary) signs Master Services Agreement with Guidehouse for enterprise revenue cycle management.","Initial term of 8 years with successive 2-year extensions; PMG can terminate without cause during extension with 180 days' notice.","Fees include monthly amount per Guidehouse employee, base advisory fees, and performance-based advisory fees tied to metrics.","Agreement includes customary representations, warranties, indemnities, and termination rights for breach, insolvency, or regulatory changes.","Statement of work #1 provides one-year term for specific services with performance metrics driving advisory fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254731,"accession_number":"0000950170-24-016790","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q4 GAAP loss $1.50/share; adj EPS $0.32; 2024 EBITDA guidance $200-220M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted loss from continuing ops $1.50 vs income $0.29 a year ago; $168.3M non-cash impairment.","Adj EPS $0.32 (down from $0.47); net revenue $496M (-3.4% YoY); same-unit revenue -1.5%.","Q4 adjusted EBITDA $50.8M (vs $66.5M); full-year adj EBITDA $200.4M (vs $241M).","Preliminary 2024 adj EBITDA guidance $200-220M, roughly flat to down from 2023.","Net AR $272.3M; total debt $628M; no revolver borrowings; cash from ops $72.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":1994640000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272205,"accession_number":"0000950170-23-057732","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q3 GAAP EPS $0.26, Adjusted EPS $0.32; FY guidance $200-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP EPS $0.26 vs $0.35 YoY; Adjusted EPS $0.32 vs $0.40.","Net revenue $506.6M (+3.4% YoY) but same-unit patient volume declined 1.2%.","Adjusted EBITDA $50.4M, down 13.5% from $58.3M; practice costs rose to $368.4M.","FY2023 Adjusted EBITDA guidance $200-210M; first nine months $149.6M implies soft Q4.","Terminated R1 RCM contract effective Dec 15, 2023; plans hybrid revenue cycle model."],"consensus_eps_estimate":null,"consensus_eps_actual":0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":1498197000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289047,"accession_number":"0000950170-23-037559","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q2 net revenue $500.6M (+3% YoY); GAAP EPS $0.34, adjusted $0.39; EBITDA $59M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS from continuing ops $0.34 vs $0.36; adjusted EPS $0.39 vs $0.47 in prior year.","Adjusted EBITDA $59.1M vs $65.6M YoY; 2023 EBITDA guidance reaffirmed at $235-245M.","Same-unit revenue up 3.2% (reimbursement +2.6%, volume +0.6%); no CARES Act funds in Q2.","Cash from ops $92.6M (+$11M YoY); capex $8.1M; total debt $675M.","Weighted average shares fell to 82.7M from 85.6M due to share repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":991585000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309785,"accession_number":"0000950170-23-021326","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pediatrix Medical Group shareholders elect directors, ratify auditor, approve say-on-pay at 2023 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected; Michael Rucker received lowest support with 68.6M for, 7.3M against.","Ratified PricewaterhouseCoopers as independent auditor for FY2023 (74.4M for, 4.3M against).","Advisory vote on 2022 executive compensation passed with 73.6M for, 2.3M against.","Shareholders indicated preference for annual advisory votes on exec comp (71.9M for one year).","Board adopted annual frequency for future say-on-pay votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309784,"accession_number":"0000950170-23-017882","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pediatrix appoints Sylvia Young as independent director effective May 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to nine; Ms. Young appointed as independent director.","Young recently served as President/CEO of HCA Continental Division, retired March 2023.","She will receive standard non-employee director compensation and enter indemnification agreement.","No material transactions or arrangements with Young; no committee assignments yet.","Appointment effective May 12, 2023; press release issued May 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309783,"accession_number":"0000950170-23-016427","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q1 net rev $491M, GAAP EPS $0.17, adj EPS $0.23, reaffirms FY adj EBITDA $235-245M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $491M, up 1.8% YoY; same-unit revenue up 2.0% driven by volume and collections.","GAAP EPS $0.17; adjusted EPS $0.23; prior year adjusted EPS $0.33 (incl $0.07 CARES benefit).","Adjusted EBITDA $40.1M vs $50.7M YoY; FY 2023 guidance reaffirmed at $235-245M.","Cash used in ops $100.6M; total debt $752M; share count decreased due to 2022 buybacks.","No CARES Act revenue recorded in Q1 2023 vs $10.4M in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":491008000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328482,"accession_number":"0000950170-23-006748","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO James D. Swift elected to Pediatrix board after director Roger J. Medel resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roger J. Medel resigned from the Board effective March 7, 2023; no disagreement with the Company.","CEO James D. Swift elected to Board to fill the vacancy created by Medel's resignation.","Swift receives no additional compensation for board service beyond his CEO pay.","Medel's resignation and Swift's election occurred on March 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328481,"accession_number":"0000950170-23-003125","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q4 GAAP EPS $0.29, adjusted $0.47; revenue $514M; 2023 EBITDA guidance $235-245M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $513.8M (+3.1% YoY); same-unit patient volume +4.1%; commercial payor mix improved 20 bps.","GAAP diluted EPS $0.29 vs $0.47; Adjusted EPS $0.47 vs $0.52; CARES Act benefit declined materially.","Adjusted EBITDA $66.5M vs $81.0M; full year 2022 Adjusted EBITDA $241.0M, GAAP EPS $0.74.","2023 preliminary Adjusted EBITDA guidance $235-245M, assuming no additional CARES Act funds.","Revenue cycle management vendor underperformance partly offset by vendor support; overhead costs reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":1972021000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346138,"accession_number":"0000950170-22-026632","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pediatrix appoints Dr. James Swift as CEO; Mark Ordan becomes Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James D. Swift, M.D., named CEO effective Jan 1, 2023; succeeds Mark S. Ordan.","Mark Ordan appointed Executive Chair of the Board; Guy Sansone becomes Lead Independent Director.","Swift's base salary increased to $650,000; annual bonus opportunity set at 125% of base.","Ordan to receive $60,000 monthly fee as Executive Chair through June 30, 2023.","Swift, a physician and former COO, joined Pediatrix in 2009 through an acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346137,"accession_number":"0000950170-22-021516","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q3 adjusted EPS $0.40 misses; FY2022 EBITDA guidance lowered to $240-245M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS from continuing operations $0.40 vs $0.46 YoY; GAAP EPS $0.35.","Net revenue $490M, down slightly from $493M YoY; same-unit revenue declined 3.2%.","Adjusted EBITDA $58.3M, down from $73.4M YoY; FY2022 guidance $240-245M.","CEO cites operational challenges in billing/collections and payor mix as headwinds.","Steps underway with R1 partner to improve revenue cycle; cost cuts starting Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1458177000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362542,"accession_number":"0001193125-22-250187","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pediatrix GC Dominic Andreano to step down; Mary Ann Moore appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andreano to depart as EVP, General Counsel and Secretary effective Oct. 14, 2022.","Termination is without cause; he will receive benefits after signing release.","He intends to enter into a consulting agreement to advise the company post-transition.","Mary Ann Moore, EVP, Chief Enterprise Risk & Legal Operations, will succeed as GC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362541,"accession_number":"0000950170-22-014467","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q2 adjusted EPS $0.47 vs $0.41 YoY; revenue up 2.7%; FY22 EBITDA outlook reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.36 flat YoY; adjusted EPS $0.47 vs $0.41 on revenue of $486M (+2.7%).","Same-unit revenue down 1.3%; volume up 0.6% offset by reimbursement decline of 1.9%.","Adjusted EBITDA flat at $65.6M; FY22 outlook reaffirmed at $260-270M.","Repurchased 3.3M shares for $64.4M in Q2; total debt $800M after refinancing.","Interest expense fell to $8.4M from $16.9M due to Q1 refinancing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":968262000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382112,"accession_number":"0000950170-22-011839","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mednax to rename to Pediatrix Medical Group effective July 1, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corporate name changes from Mednax, Inc. to Pediatrix Medical Group, Inc. after market close on July 1, 2022.","Common stock will continue to trade on NYSE under ticker symbol \"MD\" unchanged.","No shareholder action required; existing stock certificates remain valid post-name change.","CEO Mark Ordan says name change underscores focus on women, babies, and children care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382111,"accession_number":"0000950170-22-010201","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Mednax appoints James D. Swift as COO; shareholders reject say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James D. Swift, MD promoted from EVP/Chief Development Officer to EVP/COO, effective May 12, 2022.","Say-on-pay vote failed: 45.2 million against vs 34.6 million for (56.6% against).","All director nominees elected; Weiss and Starcher each received over 9 million against votes.","Ratification of PwC as auditor for FY2022 passed with 78.3 million votes for.","Shareholders approved Second Amended and Restated Articles of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382110,"accession_number":"0000950170-22-006426","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mednax Q1 GAAP loss $0.25/sh includes $57M debt charge; adj EPS $0.33","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $482M (+8% YoY); same-unit revenue +1.3%, volume +3.2%.","GAAP loss from continuing ops $20.9M ($0.25/sh) vs income $5.4M ($0.06/sh) prior year.","Adjusted EPS $0.33 vs $0.24 prior year; Adjusted EBITDA $50.7M vs $45.5M.","Issued $400M 5.375% notes due 2030; redeemed $1.0B 6.25% notes due 2027, causing $57M loss.","Cash from ops used $89.9M; total debt $799M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":482229000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400051,"accession_number":"0000950170-22-002114","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mednax President of Pediatrix and Obstetrix Medical Group Roger Mack Hinson to step down effective June 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hinson will transition from his role as President effective June 1, 2022.","Termination is without 'Cause' under his Amended and Restated Employment Agreement.","Company and Dr. Hinson intend to enter a consulting agreement for advisory services post-transition.","No replacement for the President role has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400050,"accession_number":"0000950170-22-001386","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mednax Q4 EPS $0.47 ($0.52 adj); revenue $499M; FY22 EBITDA guidance at least $270M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS from continuing ops $0.47 versus $0.05 in Q4 2020; adjusted EPS $0.52 versus $0.25.","Revenue $498.5M (+20% YoY), driven by 17.6% same-unit growth (volume +6.3%, reimbursement +11.3%).","Adjusted EBITDA $81M in Q4 ($58.3M prior year); full-year 2021 $265.5M.","Preliminary 2022 adjusted EBITDA guidance at least $270M, excluding CARES Act funds.","Post-quarter refinancing: issued $400M 5.375% notes due 2030, new $450M revolver, $250M term loan; total debt $750M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1911191000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400049,"accession_number":"0000950170-22-001148","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Mednax closes $1.1B financing, redeems $1B 6.25% notes due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $400M 5.375% senior notes due 2030, new $450M revolver and $250M term loan.","Used proceeds plus cash to redeem all $1B of 6.25% senior notes due 2027.","Outstanding debt reduced to ~$750M; net proceeds from notes ~$394.5M after discounts.","Credit agreement amended with SOFR-based pricing, matures Feb 2027; lower margins.","Notes callable at make-whole before Feb 2025, then step-down redemption prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419017,"accession_number":"0000950170-21-004821","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Mednax CFO Richards named PAO; Board adopts majority vote for directors; Moore promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO C. Marc Richards adds Principal Accounting Officer role effective immediately; John Pepia remains SVP/Chief Accounting Officer.","Board adopted Second Amended Bylaws switching director election standard from plurality to majority in non-contested elections.","Mary Ann Moore promoted to EVP & Chief Enterprise Risk and Legal Operations Officer from SVP & Chief Legal Officer, Operations.","No new compensatory arrangements disclosed for Richards beyond his existing September 2020 employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419016,"accession_number":"0000950170-21-002405","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mednax reports Q3 GAAP EPS $0.37 from continuing ops, revenue $493M, adjusted EPS $0.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $492.9M, up 7% YoY; same-unit revenue +5.9%, driven by 6.5% volume increase.","GAAP EPS $0.37 vs loss $0.03 prior year; Adjusted EPS $0.46 vs $0.37.","Adjusted EBITDA $73.4M vs $72.8M; no CARES Act funds in Q3 2021 vs $14.2M in Q3 2020.","Used $20M to invest in Brave Care; redeemed $750M 5.25% notes in Jan; cut revolver to $600M from $1.2B.","Cash at Sep 30: $358M; net debt $642M; no debt on revolver."],"consensus_eps_estimate":null,"consensus_eps_actual":0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":1412661000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436601,"accession_number":"0000950170-21-001577","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mednax cuts revolving credit commitments from $1.2B to $600M; no outstanding balance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving commitments reduced from $1.2 billion to $600 million effective August 23, 2021.","No outstanding principal balance on Credit Agreement as of that date.","One outstanding letter of credit of $0.1 million; available amount after reduction and minimum availability requirement is $299.9 million.","Company must maintain minimum availability of $300 million through Q3 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436600,"accession_number":"0001193125-21-238355","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2021-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mednax Q2: GAAP EPS $0.36, adj EPS $0.41, revenue $473M (+14% YoY), volume strong","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $473M vs $415.4M prior year; income from cont ops $30.5M ($0.36 diluted) vs $7.1M ($0.08).","Adjusted EPS $0.41 vs $0.26; adjusted EBITDA $65.5M vs $55.7M.","Same-unit revenue +13.4% (volume +9.5%, reimbursement +3.9%); office-based services volume +23.2%.","No CARES Act funds in Q2'21 vs $5.8M in Q2'20; gain on building sale $7.3M excluded from adj metrics.","Redeemed $750M 5.25% notes due 2023 in Jan 2021; debt now $1.0B with no revolver borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":919712000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}